SLC25A24: A Potential Drug Target and Biomarker for Diseases (G727941)

Target Name: SLC25A24P1

NCBI ID: G727941

SLC25A24P1

Other Name(s): SLC25A24 pseudogene 1 | LOC727941

SLC25A24: A Potential Drug Target and Biomarker for Diseases

SLC25A24P1 (SLC25A24 pseudogene 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 17 and encodes a protein known as solute carrier family 25 member 2 (SLC25A24).

SLC25A24 is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a transmembrane protein that is involved in the transport of various substances across the blood-brain barrier, including drugs and toxins.

SLC25A24 has been shown to be involved in a number of different diseases and disorders. For example, it has been linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. It has also been shown to be involved in the development of neurodegenerative diseases, such as ALS and Huntington's disease.

In addition to its potential links to disease, SLC25A24 has also been shown to be a potential drug target. Researchers have identified several potential drug candidates that can inhibit SLC25A24's activity, and these drugs have been shown to have potential therapeutic benefits in a variety of diseases.

One of the most promising SLC25A24-based drug candidates is a compound called BHV-350. BHV-350 is a small molecule that is designed to inhibit SLC25A24's activity. Studies have shown that BHV-350 is able to significantly reduce the number of neurofibrillary tangles in mice with Alzheimer's disease, a hallmark of the disease.

Another promising SLC25A24-based drug candidate is a compound called 1E10. 1E10 is a RNA interference (RNAi) drug that is designed to knockdown SLC25A24 gene expression in cancer cells. Studies have shown that 1E10 is able to significantly reduce the growth of cancer cells that express SLC25A24, and may be an effective treatment for various types of cancer.

In addition to these drug candidates, SLC25A24 has also been shown to be a potential biomarker for a variety of diseases. For example, it has been used as a biomarker for Alzheimer's disease, and has been shown to be associated with an increased risk of the disease in individuals with certain genetic mutations.

Overall, SLC25A24 is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these conditions, and to develop effective treatments based on its properties.

Protein Name: SLC25A24 Pseudogene 1

The "SLC25A24P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A24P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets